Plandai: Green Tea Extracts Fight the Common Cold

Marketwired

BALTIMORE, MD--(Marketwired - Jul 25, 2013) - Goldman Small Cap Research, a stock market research firm focused on the small cap and microcap sectors, notes that Plandai Biotechnology Inc.'s (OTCQB: PLPL) flagship product, Phytofare™ Catechin Complex, might prove its effectiveness in targeting the ubiquitous cold and flu ailments which costs Americans billions each year.

According to the National Institute of Allergy and Infectious Diseases, Americans suffer from roughly 1 billion colds per year in the United States alone, which equates to more than one per person, per season. These maladies cause decreased productivity, missed work, missed school, and other headaches -- literally and figuratively. Measures to fight the symptoms range from homemade remedies to over-the-counter drugs. There is no known cure.

A 2007 study in the Journal of the American College of Nutrition looked at the effects of green tea catechins, specifically epigallocatechin gallate (EGCG), a powerful antioxidant, on subjects suffering from colds and flu. Over 32% fewer people in the green tea group experienced no cold and flu symptoms compared to the placebo group, and nearly 23% experienced less symptoms lasting fewer days. These results come as no surprise as EGCG and green tea catechins are found to be an inhibitor of common cold adenovirus. Leveraging these and other studies, Plandai's advanced products from Green Tea Extracts can be used to target this ever-present and growing market.

Moreover, Plandai has spent over a decade developing its Phytofare™ Catechin Complex, a green tea-derived botanical extract which has been demonstrated to achieve superior bioavailability -- the amount of a compound that is absorbed into the bloodstream. As a result, users can reduce their consumption of extract and yet still receive tremendous health benefits from the Firm's products. Plandai's Phytofare™ nutriceutical product line is set to be launched in the fourth quarter of 2013. The product's superiority will no doubt benefit top-line revenue and earnings growth especially if used as cold and flu treatment and prevention.

Goldman Small Cap Research articles and reports on Plandai as well as associated disclaimers can be accessed or downloaded in their entirety by visiting www.goldmanresearch.com.

About Goldman Small Cap Research: Led by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces small cap and micro cap stock research reports, daily stock market blogs, and popular investment newsletters. For more information, visit www.goldmanresearch.com.

A Goldman Small Cap Research report is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. Please read the report's full disclosures and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other agency. To download our research, view our disclosures, or for more information, visit www.goldmanresearch.com.

About Plandai Biotechnology, Inc. (OTCQB: PLPL): Plandai Biotechnology, Inc. and its subsidiaries develop highly bioavailable, phytonutrient rich extracts, which are being utilized to deliver a new family of drugs to safely and affordably treat a multitude of diseases and conditions. Plandai Biotechnology controls every aspect of the process, from growing the raw materials on its farms in South Africa, to producing the patented Phytofare™ extracts in-house allowing the Company to guarantee the continuity of supply as well as quality control throughout the entire process. Targeted industries for the Company's products include food and beverage, cosmeceutical, wellness, nutraceutical, anti-aging, and pharmaceutical. For more information, please visit http://www.plandaibiotech.com.

Contact:
Goldman Small Cap Research
Rob Goldman
Analyst
410-609-7100
rob@goldmanresearch.com
View Comments